(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's Engineered NanoBody Lentiviral (ENaBL) platform can genetically modify immune ...

AstraZeneca to buy EsoBiotec for up to $1 billion Deal aims to enhance cancer cell therapy capabilities AstraZeneca secures global rights to Alteogen's ALT-B4 enzyme AstraZeneca shares up almost ...

AstraZeneca has announced two separate deals that will see the company acquire EsoBiotec for up to $1 billion as well as a licensing deal with Alteogen that will expand its work in oncology and cell ...

AstraZeneca already has cell therapies in its pipeline, and it is now expanding its scope further with a deal to acquire EsoBiotec, a company in early clinical development with therapies made by ...

AstraZeneca entered into a definitive agreement to acquire Belgian cell therapy developer EsoBiotec. AstraZeneca continues to bet big on cell therapy. The Big Pharma company entered into a ...

EsoBiotec announced it has entered into a definitive agreement to be acquired by AstraZeneca (AZN). The EsoBiotec Engineered NanoBody Lentiviral platform empowers the immune system to attack ...

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “We are excited about the acquisition of EsoBiotec and the opportunity to rapidly advance their promising ...

AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up to $1 billion, expanding its treatments for cancer. EsoBiotec's ...